BIAL and Wanbang Announce Exclusive Licensing Agreement for Opicapone in China
Opicapone is a new treatment for Parkinsonís Disease approved by the European Commission in June 2016
Porto, Portugal and Xuzhou, China, January 9th, 2018 - BIAL and Jiangsu Wanbang Biopharmaceutical Group Co., Ltd. (Wanbang), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, SHA: 600196 and HKG: 02196) announced today that they have entered into an exclusive license agreement for the importation, packaging and commercialization of Opicapone in China (excluding Hong Kong, Macao and Taiwan).
Under the terms of the agreement, BIAL will receive from Wanbang an upfront license fee of 2.5 million euros and up to 12.5 million euros in further milestones.
Further information is available in the Press Release below.